<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[《中国临床新医学》杂志编辑部 -->专家论坛·胰腺外科专栏]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Common biomarkers used to predict response to neoadjuvant therapy  in pancreatic ductal adenocarcinoma]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20201102&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］</b>　Pancreatic ductal adenocarcinoma(PDAC) has a high degree of malignancy and a poor prognosis, with its morbidity increasing year by year. The treatment of PDAC depends not only on the disease staging at the time of diagnosis, but also on the complex anatomical relationships.In recent years, the preferred treatment for technically resectable lesions has gradually shifted from upfront surgery to neoadjuvant therapy. Choosing appropriate regimens and evaluating the treatment responses are critical for the best oncology outcome, especially in cases where conventional imaging methods have been proven to be unreliable. As auxiliary laboratory examination, tumor biomarkers may play a key role in treatment regimen selection and treatment monitoring. This paper will introduce the current commonly used PDAC biomarkers and discuss their potential value of applications in neoadjuvant therapy, and determine their ability to be used as treatment regimen selection, and the biomarkers to evaluate treatment progress, prognosis or potential recurrence.]]></description>
<pubDate>2020/12/5 15:52:01</pubDate>
<category><![CDATA[专家论坛·胰腺外科专栏]]></category>
<author><![CDATA[SHEN Shuo, GUO Shi-wei, JIN Gang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHEN Shuo, GUO Shi-wei, JIN Gang</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20201102&flag=1]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Construction of pancreatic cancer prognosis model based on WGCNA and ssGSEA]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20201103&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］　Objective</b>　To construct a prognostic model of pancreatic cancer through weighted gene co-expression network analysis(WGCNA) and single sample gene enrichment analysis(ssGSEA). <b>Methods</b>　The pancreatic cancer tissue transcriptome sequencing data and the patients′prognosis information were obtained. Seventeen thousand eight hundred and ten pathways in each tumor tissue were scored by ssGSEA. WGCNA, univariate analysis and Lasso regression were used to screen the parameters of each pathway. A multifactorial Cox risk proportional regression model was constructed to predict the prognosis of the patients with pancreatic cancer, and the model was evaluated. <b>Results</b>　It was found by ssGSEA that the scores of various pathways in different pancreatic cancer tissues were different, such as GO RECEPTOR REGULATOR ACTIVITY, GO MONOSACCHARIDE BINDING and other pathways, suggesting that the activities of various pathways in different patients were different, which might be an important reason for the development of different tumor outcomes. After WGCNA analysis, the dynamic shearing tree method was used to merge the similar pathway modules, and 7 pathway modules were obtained. Among them, the Blue module contained the most pathways, including 3098 pathways. The Red module had a high positive correlation with the survival status of the patients with pancreatic cancer(<i>r</i>=0.33, <i>P</i><0.001), and the Black module also had a significant correlation with the patients′survival(<i>r</i>=0.11, <i>P</i>=0.03). At the same time, the Red module(<i>r</i>=0.30, <i>P</i><0.001) and the Blue module(<i>r</i>=0.24, <i>P</i>=0.002) had a significant positive correlation with histological staging of pancreatic cancer. The Blue module(<i>r</i>=0.27, <i>P</i><0.001), the Yellow module(<i>r</i>=-0.17, <i>P</i>=0.03), the Black module(<i>r</i>=0.30, <i>P</i><0.001) and the Magenta module(<i>r</i>=0.15, <i>P</i>=0.03) were significantly related to the tumor staging of pancreatic cancer. After univariate analysis and Lasso regression were used to screen the pathways related to survival and prognosis in the Red module, a total of 11 pathways related to the survival and prognosis of pancreatic cancer patients were obtained. The multi-factor Cox regression analysis was further used to establish a multi-channel prognostic prediction model, and finally a pancreatic cancer prognostic prediction model composed of 5 pathways was obtained. The C-index was 0.7 and Akaike′s information criterion(AIC) was 776.49. The model had good prediction efficiency(AUC=0.742). <b>Conclusion</b>　WGCNA and ssGSEA techniques play a significant role in the construction of prognostic model of pancreatic cancer.]]></description>
<pubDate>2020/12/5 15:52:01</pubDate>
<category><![CDATA[专家论坛·胰腺外科专栏]]></category>
<author><![CDATA[ZHANG Jun-feng, LIU Song-song, WANG Huai-zhi]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Jun-feng, LIU Song-song, WANG Huai-zhi</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20201103&flag=1]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Several problems of surgical procedures in laparoscopic pancreaticoduodenectomy]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20201104&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］</b>　Laparoscopic pancreaticoduodenectomy(LPD) has been developed rapidly in China in the past five years. Its operation time and postoperative complications are similar to those of traditional open surgery, but it has more advantages in terms of intraoperative blood loss, postoperative hospital stay and postoperative pain. Combining the relevant domestic and foreign literatures and the experience of our team, we believe that LPD is a safe, feasible and effective surgical method. Currently, a large number of literatures have been discussed on surgical indications, resection scope, surgical approaches and anastomosis during the development of LPD. However, the accumulation of experience, more prospective studies and meta-analysis of large sample clinical data are still needed to obtain the effective results.]]></description>
<pubDate>2020/12/5 15:52:01</pubDate>
<category><![CDATA[专家论坛·胰腺外科专栏]]></category>
<author><![CDATA[SI Wei, LIU Jun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SI Wei, LIU Jun</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20201104&flag=1]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Surgical methods of pancreas and pancreatic segmental resection]]></title>
<link><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20201105&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>［Abstract］</b>　Pancreaticoduodenectomy and left-sided pancreatectomy have been traditionally used for pancreatic tumors, but their disadvantages include large surgical scope, many organs and tissues removed, large trauma and great influence on organ function.In recent years, pancreatic segmental resection with preservation of organ tissue and function has been applied more and more, which has the advantages of small surgical scope, less organ and tissue resection, less trauma and less influence on organ function. Based on the relevant literature and the experience of our team, in this paper, we summarize the disadvantages of traditional surgical methods for pancreatic tumors and the advantages, indications and problems that need to be solved in pancreatic segmental resection to improve clinicians′ understanding of pancreatic segmental resection, so as to promote its standardized application in clinical practice and benefit the patients.]]></description>
<pubDate>2020/12/5 15:52:01</pubDate>
<category><![CDATA[专家论坛·胰腺外科专栏]]></category>
<author><![CDATA[LIANG Bin, LIU Tian-qi]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIANG Bin, LIU Tian-qi</atom:name>
</atom:author>
<guid><![CDATA[https://www.zglcxyxzz.com/zglcxyyen/ch/reader/view_abstract.aspx?file_no=20201105&flag=1]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>